CClinicalTrials.gg
Not yet recruitingNCT07866924Updated Oct 8, 2026

Echocardiographic Assessment of Valvular Dysfunction in Children With CHD

An observational study in Congenital Heart Disease and Valvular Heart Disease, sponsored by Assiut University. Not yet recruiting. Open to participants aged 1 Month to 18 Years. Per ClinicalTrials.gov, last updated 2026-10-08.

Sponsored by Assiut University · Observational

Updated Oct 8, 2026Newly registeredGo to Updates ↓
Study type
Observational
Model
Case-only
Time perspective
Cross-sectional
Enrollment
100
Ages
1 Month to 18 Years
Sex
All
01

Study summary

This cross-sectional study aims to assess the type and severity of valvular dysfunction by echocardiography in children with congenital heart disease.

Read the detailed description

Valvular dysfunction is common in children with congenital heart disease and may include stenosis, regurgitation, or mixed lesions. Echocardiography is the primary non-invasive method for evaluating valve morphology and hemodynamics.

This observational study will perform comprehensive echocardiographic assessment in children aged 1 month to 18 years with congenital heart disease to determine the prevalence and characteristics of valvular dysfunction.

02

Conditions studied

  • Congenital Heart Disease
  • Valvular Heart Disease

Keywords

  • Congenital heart disease
  • Echocardiography
  • Children
  • Valvular dysfunction
  • Assiut
03

In context

Heart Defects, Congenital

1,007 studies on the registry are indexed under Heart Defects, Congenital; 257 are open to participants now.

This study's planned enrollment of 100 is below the median of 121 across 442 observational studies indexed under Heart Defects, Congenital.

Browse Heart Defects, Congenital studies →

Lead sponsor

Assiut University is the lead sponsor of 4,916 studies on the registry; 2,113 are open to participants now.

Of its 13 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
1 Month to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Children aged 1 month to 18 years with congenital heart disease attending the Cardiology Department of Assiut University Children Hospital.

Inclusion criteria

  • - Children with congenital heart disease
  • Age from 1 month to 18 years
  • Written informed consent from parents or legal guardians

Exclusion criteria

Exclusion Criteria:

  • - Rheumatic heart disease
  • Any type of cardiomyopathy
05

Study design

Observational model
Case-only
Time perspective
Cross-sectional
Enrollment
100 participants (estimated)
Patient registry
No

Groups and cohorts

  • Children with Congenital Heart Disease

    Children aged 1 month to 18 years with congenital heart disease undergoing echocardiographic assessment of valvular function.

06

What researchers measure

Primary outcomes

  1. Frequency of valvular dysfunction

    Percentage of children with congenital heart disease who have any valvular stenosis or regurgitation on echocardiography.

    Time frame: Baseline

Secondary outcomes

  1. Frequency of aortic valve dysfunction

    Percentage of children with aortic stenosis or aortic regurgitation on echocardiography.

    Time frame: Baseline

  2. Frequency of pulmonary valve dysfunction

    Percentage of children with pulmonary stenosis or pulmonary regurgitation on echocardiography.

    Time frame: Baseline

  3. Frequency of mitral valve dysfunction

    Percentage of children with mitral stenosis or mitral regurgitation on echocardiography.

    Time frame: Baseline

  4. Frequency of tricuspid valve dysfunction

    Percentage of children with tricuspid stenosis or tricuspid regurgitation on echocardiography.

    Time frame: Baseline

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

1 registry update since Sep 25, 2026
Registered
First appeared on the registry. No changes since
Oct 8, 2026
Show all 1 update
  1. Oct 8, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07866924
Lead sponsor
Assiut University
Responsible party
Mohamed Sayed Abd Elwareth (Resident Physician, Department of Pediatrics, Assiut University) — Principal investigator
First posted
Oct 8, 2026
Start date
Oct 10, 2026 (estimated)
Primary completion
Oct 10, 2027 (estimated)
Completion
Apr 1, 2028 (estimated)
Last update
Oct 8, 2026

Study contacts

Mohamed S Abelwarith, Resident
Contact
mohamed.18313430@med.aun.edu.eg
+20 10 13000660
Salah eldin A Ahmed, prof
study chair · Pediatrics Department, Assiut University Hospitals

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion